8-K: Surgery Partners Exceeds Expectations in Q2 2024, Raises Full-Year Guidance

Surgery Partners reported strong second-quarter results, exceeding expectations with significant revenue and adjusted EBITDA growth, and subsequently raised its full-year 2024 guidance.

Summary

• Surgery Partners announced its second-quarter 2024 results, showing a 14.2% increase in revenue to $762.1 million compared to the same period last year.
• Same-facility revenues grew by 9.9%, driven by a 5.7% increase in revenue per case and a 3.9% increase in same-facility cases.
• The company reported a net loss attributable to Surgery Partners, Inc. of $15.5 million.
• Adjusted EBITDA reached $118.3 million, an 18.1% increase year-over-year, with an adjusted EBITDA margin of 15.5%, a 50 basis point expansion.
• Year-to-date revenue increased by 10.9% to $1,479.5 million, and same-facility revenue grew by 10.0%.
• Year-to-date adjusted EBITDA was $215.8 million, compared to $190.3 million in the prior year period.
• The company's full-year 2024 guidance was raised to greater than $3.075 billion in revenue and greater than $508 million in Adjusted EBITDA.
• Surgery Partners deployed nearly $220 million on acquisitions during the quarter.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong financial results, raised guidance, and strategic acquisitions. The company's management expresses confidence in future growth, and the overall tone is optimistic.

Positives

• Surgery Partners exceeded expectations for both revenue and adjusted EBITDA in the second quarter.
• The company experienced strong same-facility revenue growth, indicating organic strength.
• The company successfully refinanced its term loan and unsecured bonds, increasing borrowing capacity and lowering interest rates.
• The company has a strong acquisition pipeline and is actively deploying capital for growth.
• Cash flows from operating activities increased to $82.8 million for the second quarter of 2024, compared to $52.1 million in the prior year quarter.

Negatives

• The company reported a net loss attributable to Surgery Partners, Inc. of $15.5 million for the second quarter.
• Year-to-date operating cash flows were $123.5 million compared to $126.6 million in the prior year period.
• Free cash flow was $22.4 million for year-to-date 2024.

Risks

• The company faces risks related to reductions in payments from government health care programs and private insurance payors.
• There are risks associated with maintaining relationships with physicians and managing the impact of payor controls.
• The company is exposed to risks related to integrating acquired businesses and attracting new physician partners.
• Supply chain issues, competition, and the ability to attract and retain qualified healthcare professionals pose ongoing challenges.
• The company is subject to legal and regulatory proceedings, cybersecurity risks, and the impact of economic conditions in the states where it operates.
• The company's indebtedness and the social and economic impact of pandemics are also potential risks.

Future Outlook

The company raised its full-year 2024 guidance to greater than $3.075 billion in revenue and greater than $508 million in Adjusted EBITDA, indicating a positive outlook for the remainder of the year.

Management Comments

• Wayne DeVeydt, Executive Chairman, stated that the company is proud to report strong growth in Adjusted EBITDA and revenue, both ahead of expectations.
• Eric Evans, CEO, highlighted the company's continued execution on its acquisition strategy and robust de novo pipeline.
• Dave Doherty, CFO, noted the company's actions to address balance sheet exposure to refinancing and interest rates.

Industry Context

The results reflect a positive trend in the outpatient surgical services industry, with Surgery Partners demonstrating strong growth in a competitive market. The company's focus on acquisitions and operational efficiency aligns with industry trends towards consolidation and cost-effective healthcare delivery.

Comparison to Industry Standards

• Surgery Partners' same-facility revenue growth of 9.9% in Q2 2024 is strong compared to industry averages, which typically range from 3-7% for established players in the ambulatory surgery center market.
• Competitors like AmSurg and Tenet Healthcare have also reported growth in their ambulatory surgery divisions, but Surgery Partners' growth rate appears to be at the higher end of the spectrum.
• The adjusted EBITDA margin of 15.5% is competitive, with top-tier operators in the sector often achieving margins between 15-20%.
• The company's acquisition strategy is consistent with the industry trend of consolidation to achieve economies of scale and expand market reach.

Stakeholder Impact

• Shareholders are likely to react positively to the strong financial results and raised guidance.
• Employees may benefit from the company's growth and expansion.
• Customers (patients) should continue to receive high-quality surgical care.
• Physicians may find the company an attractive partner due to its growth and strategic focus.
• Creditors may view the company's improved financial performance favorably.

Next Steps

• The company will continue to execute its acquisition strategy.
• The company will focus on operational execution and physician recruitment.
• The company will hold a conference call on August 6, 2024, to discuss the results.

Key Dates

Keywords

Surgery Partners, SGRY, Ambulatory Surgery Centers, Healthcare Services, Adjusted EBITDA, Revenue Growth, Acquisitions, Financial Results, Outpatient Surgery, Same-Facility Revenue